Orlistat for overweight subjects with nonalcoholic steatohepatitis

Authors

  • Joanna K. Dowman M.D.,

    1. Wellcome Clinical Research Fellow in Hepatology, Institute of Biomedical Research, Edgbaston, Birmingham, UK
    Search for more papers by this author
  • Deborah Stocken C.Stat.,

    1. Senior Biostatistician, Cancer Research UK Clinical Trials Unit, Edgbaston, Birmingham, UK
    Search for more papers by this author
  • Jeremy W. Tomlinson M.D., Ph.D.,

    1. Wellcome Clinician Scientist and Honorary Consultant Physician, School of Clinical and Experimental Medicine, Institute of Biomedical Research, University of Birmingham, Edgbaston, Birmingham, UK
    Search for more papers by this author
  • Philip Newsome M.D., Ph.D.

    1. Senior Lecturer in Hepatology and Honorary Consultant Physician, Centre for Liver Research, Institute of Biomedical Research, Edgbaston, Birmingham, UK
    Search for more papers by this author

  • Potential conflict of interest: Dr. Newsome is Chief Investigator in a phase II trial of an experimental product for NASH for Astellas.

No abstract is available for this article.

Ancillary